Table 2.
Variable | Meglumine Antimoniate (n = 58) | Miltefosine (n = 58) |
Primary outcome | ||
Definitive cure at week 26 | 40 | 48 |
Treatment failure | 16 | 7 |
Unavailable for follow-up | 1 | 2 |
Did not complete treatment | 1 | 1 |
Failure (98% CI), %a | ||
Per-protocol population | 28.6 (14.5–42.6) | 12.7 (2.3–23.2) |
Intention-to-treat population | 31 (16.9–45.2) | 17.2 (5.7–28.8) |
Abbreviation: CI, confidence interval.
The difference in median failure rates between treatment groups was 15.9 (98% CI, −1.7 to 33.4) for the per-protocol population and 13.8 (−4.5 to 32.0) for the intention-to-treat population.